Related Experiment Video

Updated: Feb 27, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A

Maya Leventer-Roberts1,2, Ariel Hammerman3, Ilan Brufman1

  • 1Clalit Research Institute, Tel Aviv, Israel.

Plos One
|July 8, 2017
PubMed
Abstract

Insights

Direct acting antivirals, specifically dasabuvir/ombitasvir/paritaprevir/ritonavir, show high effectiveness for hepatitis C virus (HCV) treatment. This real-world study confirms near-universal sustained virological response in a large patient cohort.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment.
  • Randomized controlled trials (RCTs) demonstrate high efficacy, but real-world data from observational cohorts are crucial.
  • Observational studies are needed to validate DAA effectiveness in patient populations with diverse characteristics and fewer exclusion criteria.

Purpose of the Study:

  • To evaluate the real-world effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response (SVR) in HCV genotype 1 patients.
  • To assess treatment outcomes in a large, unselected patient cohort treated in a routine clinical setting.

Main Methods:

  • Retrospective observational cohort study design.
  • Inclusion of all Clalit Health Services members diagnosed with HCV genotype 1 treated with dasabuvir/ombitasvir/paritaprevir/ritonavir between January 1, 2015, and November 31, 2015.
  • Analysis of sustained virological response based on viral load testing 10 or more weeks post-treatment.

Main Results:

  • A cohort of 564 participants was analyzed, with a mean age of 61.9 years.
  • The cohort exhibited significant comorbidities, including 31.7% with diabetes and 70.3% overweight/obese.
  • Cirrhosis was present in 41.0% of participants, with 52.8% having stage 4 fibrosis.
  • Among the 416 participants (74.8%) with follow-up viral load testing, a sustained virological response rate of 98.8% was achieved.

Conclusions:

  • Dasabuvir/ombitasvir/paritaprevir/ritonavir treatment is highly effective in achieving SVR in a large, real-world HCV patient cohort.
  • The findings support the use of this DAA regimen in diverse patient populations, including those with comorbidities and advanced liver disease.
  • Real-world effectiveness closely mirrors the high efficacy observed in clinical trials.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.5K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.0K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
457
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
609
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
266